Novus Therapeutics said that a Phase 2a clinical trial of its OP0201 intranasal surfactant MDI for the treatment of acute otitis media in infants and children failed to meet its primary endpoints of "resolution of bulging tympanic membrane at visit 2 and resolution of middle ear effusion at visit 3." The study did show greater resolution of middle ear effusion for … [Read more...] about Phase 2a trial of Novus’s OP0201 nasal MDI for otitis media fails to meet primary endpoints
Business
Atossa Therapeutics announces development of intranasal therapy for mild COVID-19
Atossa Therapeutics announced that it has signed an agreement with Summit Biosciences for development and manufacturing of an intranasal formulation of Atossa's AT-301 as a candidate for the treatment of mild COVID-19, and it plans to submit an IND for clinical trials expected to begin in the third quarter of this year. The company said it is also investigating the … [Read more...] about Atossa Therapeutics announces development of intranasal therapy for mild COVID-19
CARB-X and CF Foundation award Microbion grants worth up to $17 million for development of inhaled pravisbismane
Microbion Corporation said that it has received a grant worth up to $11.5 million from global non-profit CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and a grant worth up to $5.6 million from the Cystic Fibrosis Foundation (CFF) for pre-clinical and Phase 1 development of its pravibismane inhalation suspension for the treatment of … [Read more...] about CARB-X and CF Foundation award Microbion grants worth up to $17 million for development of inhaled pravisbismane
Teva Canada imports supply of UK-branded salbutamol (albuterol) MDIs under interim order
Teva Canada said that it has imported a 4-week supply of Salamol salbutamol (albuterol) sulfate MDIs through Teva UK under an interim order by the Minister of Health in response to shortages of the inhalers in Canada caused by the COVID-19 pandemic. Salamol MDIs are marketed by IVAX Pharmaceuticals in the UK; Teva acquired IVAX in 2006. Health Canada recently … [Read more...] about Teva Canada imports supply of UK-branded salbutamol (albuterol) MDIs under interim order
Senzer to develop inhaled antivirals for the treatment of COVID-19
Senzer Pharmaceuticals has announced the launch of a new Critical Care Division for development of two inhaled anti-viral drugs for the treatment of COVID-19. The company did not specify which drugs it planned to develop but did say that the formulations would be delivered via MDI rather than with its SIDD (Systemic Inhaled Delivery Device), which is used for its … [Read more...] about Senzer to develop inhaled antivirals for the treatment of COVID-19
Glenmark launches Airz-FF triple combination inhaler for COPD in India
Glenmark Pharmaceuticals has announced the launch of its Airz-FF glycopyrronium/formoterol/fluticasone propionate triple combination inhaler for the treatment of COPD in India. The company said that "AIRZ-FF has been exclusively studied in the Indian population and introduced to address challenges faced by a significant portion of COPD patients in the … [Read more...] about Glenmark launches Airz-FF triple combination inhaler for COPD in India
Iconovo says Amneal will take over development of ICOres-based generic Symbicort
DPI developer Iconovo has announced that Amneal will take over development of a generic version of Symbicort based on Iconovo's multi-dose ICOres device. Iconovo and Amneal initially signed a licensing and development deal in 2016. In March 2019, Iconovo had announced that Mumbai-based CBC Corporation would handle development of the DPI. According to the new … [Read more...] about Iconovo says Amneal will take over development of ICOres-based generic Symbicort
Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Alnylam Pharmaceuticals and Vir Biotechnology have announced that they intend to meet with the FDA soon regarding an IND for VIR-2703 (ALN-COV), an inhaled siRNA in development for prevention and/or treatment of COVID-19. The companies said that VIR-2703 may also have activity against other coronaviruses. The collaboration agreement between Vir and Alnylam includes … [Read more...] about Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG's "Emergency Call to research COVID-19 in the wake of the outbreak of SARS-CoV-2." Carragelose is a polymer derived from red seaweed that has shown activity against … [Read more...] about Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Avalyn Pharma raises $35.5 million for development of inhaled pirfenidone
Avalyn Pharma (formerly Genoa Pharmaceuticals) announced that it has raised $35.5 million in a Series B financing round led by Norwest Venture Partners. The proceeds will fund a Phase 2/3 trial Avalyn's AP01 nebulized pirfenidone for the treatment of chronic lung allograft dysfunction in lung transplant patients. AP01 is also in development for the treatment of … [Read more...] about Avalyn Pharma raises $35.5 million for development of inhaled pirfenidone